Physician profile
Donna E Ryan
NPI 1396922993
$2,400.48
in general payments reported to CMS, 2019-2025
23 companies · $693 in 2025
The $693 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $236 · 2022: $318 · 2023: $538 · 2024: $615 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,846.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $552.50 | 2021-2025 | |
| Novo Nordisk INC | $510.18 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $232.47 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $199.65 | 2021-2025 | Shingrix, Arexvy |
| Abbvie INC. | $184.93 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $113.94 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Lilly USA, LLC | $108.06 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $66.10 | 2024-2025 | Breztri, Farxiga |
| Kaleo, INC. | $54.02 | 2021-2022 | |
| Seqirus USA INC | $51.11 | 2023-2024 | Flucelvax, Fluad, Fluad Quadrivalent |
| Otsuka America Pharmaceutical, INC. | $50.03 | 2023-2024 | Rexulti |
| Amgen INC. | $48.97 | 2025 | |
| Boston Scientific Corporation | $37.82 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $32.76 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $31.87 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $27.56 | 2021-2022 | |
| Abbott Laboratories | $16.15 | 2022 | |
| Medicomp INC | $16.02 | 2024 | Telepatch Cardiac Monitor |
| Cumberland Pharmaceuticals, INC. | $14.22 | 2024 | Kristalose |
| Esperion Therapeutics, INC. | $14.21 | 2021 | |
| Paratek Pharmaceuticals, INC. | $13.69 | 2024 | Nuzyra |
| Amarin Pharma, INC. | $12.50 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.